Do you see any role for PARP inhibitors in NSCLC given the recent PIN trial of maintenance olaparib did not show significant improvement in PFS?
Based on results of the recently published study.
Answer from: Medical Oncologist at Community Practice
The short answer is yes, a role for PARP inhibition in NSCLC may still exist for select patients. The Olaparib Maintenance versus Placebo Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer trial (PIN) evaluated the use of olaparib as maintenance therapy in patients who had tumor respon...
Sign in or Register to read more